Tibotec gets Incivo approved in Europe
This article was originally published in Scrip
Executive Summary
Tibotec Virco-Virology, a Janssen Pharmaceutical (J&J) subsidiary, will launch Incivo (telaprevir), its treatment for hepatitis C virus in Germany within the next week or so, following approval from the European Commission on 20 September 2011.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.